SE504074C2 - Proteinberedning för subkutan, intramuskulär eller intradermal administrering - Google Patents

Proteinberedning för subkutan, intramuskulär eller intradermal administrering

Info

Publication number: SE504074C2
Authority: SE; Sweden
Prior art keywords: factor viii; subcutaneous; intramuscular; preparation; viii
Prior art date: 1993-07-05

Application number

SE9302308A

Other languages

English (en)

Swedish (sv)

Other versions

SE9302308L (sv

SE9302308D0 (sv

Inventor

Jack Spira

Lars Widlund

Thomas Oesterberg

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-05

Filing date

1993-07-05

Publication date

1996-11-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE504074(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-07-05 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

1993-07-05 Priority to SE9302308A priority Critical patent/SE504074C2/sv

1993-07-05 Publication of SE9302308D0 publication Critical patent/SE9302308D0/xx

1994-03-23 Priority to ZA942035A priority patent/ZA942035B/xx

1994-03-30 Priority to MX9402339A priority patent/MX9402339A/es

1994-03-31 Priority to PT94915722T priority patent/PT710114E/pt

1994-03-31 Priority to JP50398795A priority patent/JP3827713B2/ja

1994-03-31 Priority to AT94915722T priority patent/ATE233099T1/de

1994-03-31 Priority to US08/564,161 priority patent/US5972885A/en

1994-03-31 Priority to CA002163112A priority patent/CA2163112C/en

1994-03-31 Priority to ES94915722T priority patent/ES2193159T5/es

1994-03-31 Priority to EP94915722A priority patent/EP0710114B2/de

1994-03-31 Priority to PCT/SE1994/000297 priority patent/WO1995001804A1/en

1994-03-31 Priority to AU67627/94A priority patent/AU6762794A/en

1994-03-31 Priority to DK94915722.6T priority patent/DK0710114T4/da

1994-03-31 Priority to DE69432179T priority patent/DE69432179T3/de

1994-03-31 Priority to SE9401105A priority patent/SE9401105D0/

1995-01-06 Publication of SE9302308L publication Critical patent/SE9302308L/

1996-11-04 Publication of SE504074C2 publication Critical patent/SE504074C2/sv

Links

238000007920 subcutaneous administration Methods 0.000 title claims abstract description 18
238000007918 intramuscular administration Methods 0.000 title claims abstract description 11
238000002360 preparation method Methods 0.000 title claims description 26
108090000623 proteins and genes Proteins 0.000 title description 7
102000004169 proteins and genes Human genes 0.000 title description 6
108010054218 Factor VIII Proteins 0.000 claims abstract description 44
102000001690 Factor VIII Human genes 0.000 claims abstract description 44
229960000301 factor viii Drugs 0.000 claims abstract description 38
239000000203 mixture Substances 0.000 claims abstract description 13
239000003814 drug Substances 0.000 claims abstract description 10
238000012217 deletion Methods 0.000 claims abstract description 8
230000037430 deletion Effects 0.000 claims abstract description 8
239000008280 blood Substances 0.000 claims abstract description 7
210000004369 blood Anatomy 0.000 claims abstract description 7
238000004519 manufacturing process Methods 0.000 claims abstract description 7
208000031220 Hemophilia Diseases 0.000 claims abstract description 6
208000009292 Hemophilia A Diseases 0.000 claims abstract description 6
238000011282 treatment Methods 0.000 claims abstract description 6
229940105778 coagulation factor viii Drugs 0.000 claims abstract description 5
238000009472 formulation Methods 0.000 claims abstract 6
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 24
108010025139 recombinant factor VIII SQ Proteins 0.000 claims description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
229960002885 histidine Drugs 0.000 claims description 12
229940024606 amino acid Drugs 0.000 claims description 10
150000001413 amino acids Chemical class 0.000 claims description 10
239000011780 sodium chloride Substances 0.000 claims description 10
-1 polyoxyethylene Polymers 0.000 claims description 8
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
239000001110 calcium chloride Substances 0.000 claims description 6
229910001628 calcium chloride Inorganic materials 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 5
102000009027 Albumins Human genes 0.000 claims description 4
108010088751 Albumins Proteins 0.000 claims description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
229960004494 calcium gluconate Drugs 0.000 claims description 4
239000004227 calcium gluconate Substances 0.000 claims description 4
235000013927 calcium gluconate Nutrition 0.000 claims description 4
159000000007 calcium salts Chemical class 0.000 claims description 4
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
235000014113 dietary fatty acids Nutrition 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
229930195729 fatty acid Natural products 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000872 buffer Substances 0.000 description 7
241000699670 Mus sp. Species 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000002736 nonionic surfactant Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000000034 method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
229960005069 calcium Drugs 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
238000000746 purification Methods 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000008227 sterile water for injection Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
101000856746 Bos taurus Cytochrome c oxidase subunit 7A1, mitochondrial Proteins 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000006173 Good's buffer Substances 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000012564 Q sepharose fast flow resin Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940078512 calcium gluceptate Drugs 0.000 description 1
FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000001112 coagulating effect Effects 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
235000006109 methionine Nutrition 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
229920002114 octoxynol-9 Polymers 0.000 description 1
229940098514 octoxynol-9 Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000006152 selective media Substances 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SE9302308A 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering SE504074C2 (sv)

Priority Applications (15)

Application Number	Priority Date	Filing Date	Title
SE9302308A SE504074C2 (sv)	1993-07-05	1993-07-05	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
ZA942035A ZA942035B (en)	1993-07-05	1994-03-23	Protein formulation
MX9402339A MX9402339A (es)	1993-07-05	1994-03-30	Formulacion de proteina.
SE9401105A SE9401105D0 (sv)	1993-07-05	1994-03-31	Formulation
DE69432179T DE69432179T3 (de)	1993-07-05	1994-03-31	Eine formulierung des gerinnungsfaktors viii
CA002163112A CA2163112C (en)	1993-07-05	1994-03-31	A coagulation factor viii formulation
PCT/SE1994/000297 WO1995001804A1 (en)	1993-07-05	1994-03-31	A coagulation factor viii formulation
AT94915722T ATE233099T1 (de)	1993-07-05	1994-03-31	Eine formulierung des gerinnungsfaktors viii
US08/564,161 US5972885A (en)	1993-07-05	1994-03-31	Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives
PT94915722T PT710114E (pt)	1993-07-05	1994-03-31	Formulacao do factor viii de coagulacao
ES94915722T ES2193159T5 (es)	1993-07-05	1994-03-31	Una formulación de factor de coagulación viii.
EP94915722A EP0710114B2 (de)	1993-07-05	1994-03-31	Eine formulierung des gerinnungsfaktors viii
JP50398795A JP3827713B2 (ja)	1993-07-05	1994-03-31	凝固因子ｖｉｉｉからなる医薬製剤
AU67627/94A AU6762794A (en)	1993-07-05	1994-03-31	A coagulation factor viii formulation
DK94915722.6T DK0710114T4 (da)	1993-07-05	1994-03-31	Koagulationsfaktor VIII-formulering

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9302308A SE504074C2 (sv)	1993-07-05	1993-07-05	Proteinberedning för subkutan, intramuskulär eller intradermal administrering

Publications (3)

Publication Number	Publication Date
SE9302308D0 SE9302308D0 (sv)	1993-07-05
SE9302308L SE9302308L (sv)	1995-01-06
SE504074C2 true SE504074C2 (sv)	1996-11-04

Family

ID=20390516

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SE9302308A SE504074C2 (sv)	1993-07-05	1993-07-05	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9401105A SE9401105D0 (sv)	1993-07-05	1994-03-31	Formulation

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SE9401105A SE9401105D0 (sv)	1993-07-05	1994-03-31	Formulation

Country Status (14)

Country	Link
US (1)	US5972885A (de)
EP (1)	EP0710114B2 (de)
JP (1)	JP3827713B2 (de)
AT (1)	ATE233099T1 (de)
AU (1)	AU6762794A (de)
CA (1)	CA2163112C (de)
DE (1)	DE69432179T3 (de)
DK (1)	DK0710114T4 (de)
ES (1)	ES2193159T5 (de)
MX (1)	MX9402339A (de)
PT (1)	PT710114E (de)
SE (2)	SE504074C2 (de)
WO (1)	WO1995001804A1 (de)
ZA (1)	ZA942035B (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL113010A0 (en) *	1994-03-31	1995-10-31	Pharmacia Ab	Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) *	1994-11-14	1994-11-14	Annelie Almstedt	Process A
US7244824B2 (en)	1995-01-19	2007-07-17	Quadrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
US7253262B2 (en)	1995-01-19	2007-08-07	Quandrant Drug Delivery Limited	Dried blood factor composition comprising trehalose
GB9501040D0 (en)	1995-01-19	1995-03-08	Quadrant Holdings Cambridge	Dried composition
SE9502285D0 (sv)	1995-06-22	1995-06-22	Pharmacia Ab	Improvements related to injections
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US7560107B2 (en) *	1996-06-26	2009-07-14	Emory University	Modified factor VIII
US5763401A (en) *	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DE69934890D1 (de) *	1998-06-16	2007-03-08	Univ Oklahoma	Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung
US7223845B2 (en)	1998-06-16	2007-05-29	The Board Of Regents Of The University Of Oklahoma	Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) *	1998-06-16	2003-07-31	Cummings Richard D.	Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
EP2921180B1 (de)	1999-02-22	2019-08-14	University of Connecticut	Albuminfreie Faktor-VIII-Formulierungen
GB0207092D0 (en)	2002-03-26	2002-05-08	Sod Conseils Rech Applic	Stable pharmaceutical composition containing factor VIII
WO2004075923A2 (en) *	2003-02-26	2004-09-10	Nektar Therapeutics Al, Corporation	Polymer-factor viii moiety conjugates
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
CA2465004A1 (en) *	2003-05-19	2004-11-19	National Institute For Biological Standards And Control	Composition
CN1266144C (zh) *	2003-09-01	2006-07-26	上海凯曼生物科技有限公司	黄芩甙和黄芩甙元的用途和剂型
ES2229931B1 (es) *	2003-10-03	2006-01-16	Grifols, S.A.	Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
DE102004005095A1 (de)	2004-01-27	2005-09-22	Coty B.V.	Kosmetische Zusammensetzung mit wasserbeständiger Parfümkomponente
SI1750733T1 (sl) *	2004-05-03	2014-03-31	Emory University	POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
KR101468345B1 (ko) *	2004-11-12	2014-12-03	바이엘 헬스케어 엘엘씨	Ｆｖｉｉｉ의 부위 지향 변형
TWI264608B (en) *	2005-04-08	2006-10-21	Delta Electronics Inc	Light tunnel module
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
CA2670618C (en)	2006-12-15	2016-10-04	Baxter International Inc.	Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
ES2392569T3 (es)	2007-06-13	2012-12-11	Csl Behring Gmbh	Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
NZ593190A (en)	2008-11-07	2013-01-25	Baxter Int	Factor viii formulations
CA2748314C (en)	2009-02-03	2018-10-02	Amunix Operating Inc.	Extended recombinant polypeptides and compositions comprising same
US10172949B2 (en)	2009-06-09	2019-01-08	Prolong Pharmaceuticals, LLC	Hemoglobin compositions
US10172950B2 (en)	2009-06-09	2019-01-08	Prolong Pharmaceuticals, LLC	Hemoglobin compositions
KR102170375B1 (ko) *	2009-06-09	2020-10-27	프로롱 파마슈티컬스, 엘엘씨	헤모글로빈 조성물
CN102497884A (zh)	2009-07-27	2012-06-13	巴克斯特国际公司	凝血蛋白缀合物
US8642737B2 (en)	2010-07-26	2014-02-04	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
US8809501B2 (en)	2009-07-27	2014-08-19	Baxter International Inc.	Nucleophilic catalysts for oxime linkage
KR101912335B1 (ko)	2009-07-27	2018-10-26	리폭센 테크놀로지즈 리미티드	비혈액 응고 단백질의 글리코폴리시알화
CN106110311A (zh)	2009-07-27	2016-11-16	百深公司	凝血蛋白缀合物
KR20120061898A (ko) *	2009-08-20	2012-06-13	체에스엘 베링 게엠베하	출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
PL3326643T3 (pl)	2009-12-06	2021-10-25	Bioverativ Therapeutics Inc.	Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
GB201007356D0 (en)	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIIa
SG10201505217WA (en)	2010-07-09	2015-08-28	Biogen Hemophilia Inc	Chimeric clotting factors
EP2591101B1 (de)	2010-07-09	2018-11-07	Bioverativ Therapeutics Inc.	Systeme für faktor viii-verarbeitung und verfahren davon
EP2616486B1 (de)	2010-09-15	2019-01-02	Stichting Sanquin Bloedvoorziening	Faktor-viii-varianten mit reduzierter zellulärer aufnahme
JP5922141B2 (ja)	2010-11-05	2016-05-24	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
HUE049352T2 (hu)	2010-12-22	2020-09-28	Baxalta GmbH	Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
US9422338B2 (en)	2011-05-19	2016-08-23	Epodose Llc	Compounds that bind to the erythropoietin receptor
CA2838833A1 (en)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof
ES2682249T3 (es) *	2011-06-10	2018-09-19	Baxalta GmbH	Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
CN103796670A (zh)	2011-07-08	2014-05-14	比奥根艾迪克依蒙菲利亚公司	因子viii嵌合和杂合多肽及其使用方法
WO2013016454A1 (en)	2011-07-25	2013-01-31	Biogen Idec Hemophilia Inc.	Assays to monitor bleeding disorders
CN103889445A (zh)	2011-10-18	2014-06-25	德国杰特贝林生物制品有限公司	硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
CA2851057A1 (en)	2011-10-18	2013-04-25	Csl Behring Gmbh	Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
EP3970737A1 (de)	2012-01-12	2022-03-23	Bioverativ Therapeutics Inc.	Reduzierung der immunogenität gegen den faktor viii bei patienten in einer faktor-viii-therapie
DK2804623T3 (da)	2012-01-12	2019-11-11	Bioverativ Therapeutics Inc	Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
EP2858659B1 (de)	2012-06-08	2019-12-25	Bioverativ Therapeutics Inc.	Prokoagulationsverbindungen
JP2015525222A (ja)	2012-06-08	2015-09-03	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	キメラ性凝固因子
EP3404105A1 (de)	2012-07-06	2018-11-21	Bioverativ Therapeutics Inc.	Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
HRP20200007T1 (hr)	2012-07-11	2020-03-20	Bioverativ Therapeutics Inc.	Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
US10001495B2 (en)	2012-07-25	2018-06-19	Bioverativ Therapeutics Inc.	Blood factor monitoring assay and uses thereof
CA2888806A1 (en)	2012-10-18	2014-04-24	Biogen Idec Ma Inc.	Methods of using a fixed dose of a clotting factor
EP3446700A1 (de)	2012-10-30	2019-02-27	Bioverativ Therapeutics Inc.	Verfahren zur verwendung von fviii-polypeptid
SI3889173T1 (sl)	2013-02-15	2023-11-30	Bioverativ Therapeutics Inc.	Optimiran gen dejavnika VIII
AR095527A1 (es)	2013-03-15	2015-10-21	Biogen Idec Inc	Formulaciones de polipéptido fc-factor ix
DK2968477T3 (da)	2013-03-15	2020-03-09	Bioverativ Therapeutics Inc	Faktor viii-polypeptidformuleringer
EP2989123A4 (de) *	2013-04-22	2016-10-12	Scripps Research Inst	Verfahren und zusammensetzungen zur behandlung von blutungsstörungen
EP2796145B1 (de)	2013-04-22	2017-11-01	CSL Ltd.	Ein kovalenter komplex bestehend aus von willebrand und faktor viii verbunden mit einer disulfidbrücke
SG10201710616XA (en)	2013-06-28	2018-02-27	Biogen Ma Inc	Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en)	2013-08-08	2015-02-12	Biogen Idec Ma Inc.	Purification of chimeric fviii molecules
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en)	2013-11-08	2020-03-10	Biovertiv Therapeutics Inc.	Procoagulant fusion compound
US10325687B2 (en)	2013-12-06	2019-06-18	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
AU2015204646B2 (en)	2014-01-10	2020-08-27	Bioverativ Therapeutics Inc.	Factor VIII chimeric proteins and uses thereof
KR102382402B1 (ko)	2014-02-04	2022-04-01	바이오젠 엠에이 인코포레이티드	번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3152230B1 (de)	2014-06-06	2019-08-07	Octapharma AG	Zubereitung mit faktor-viii- und von-willebrand-faktor-peptiden
EP3160478A4 (de)	2014-06-30	2018-05-16	Bioverativ Therapeutics Inc.	Optimiertes faktor-ix-gen
US9987241B2 (en)	2014-09-25	2018-06-05	The Board Of Regents Of The University Of Oklahoma	Enzyme conjugate and prodrug cancer therapy
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
EP3374387A1 (de)	2015-11-13	2018-09-19	Baxalta Incorporated	Virale vektoren zur codierung von rekombinanten fviii-varianten mit erhöhter expression zur gentherapie von hämophilie a
EA202092049A1 (ru)	2015-11-13	2020-11-10	Баксалта Инкорпорейтед	Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
WO2017136358A1 (en)	2016-02-01	2017-08-10	Bioverativ Therapeutics Inc.	Optimized factor viii genes
CN109790529A (zh)	2016-06-24	2019-05-21	财团法人牧岩生命科学研究所	包含FVIII和vWF因子的嵌合蛋白及其用途
CA3043397A1 (en)	2016-11-11	2018-05-17	CSL Behring Lengnau AG	Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
IL319473A (en)	2016-12-02	2025-05-01	Bioverativ Therapeutics Inc	Methods for treating hemophilic arthritis using chimeric blood clotting factors
CN110520149A (zh)	2016-12-02	2019-11-29	比奥维拉迪维治疗股份有限公司	诱导对凝血因子的免疫耐受性的方法
WO2020032951A1 (en)	2018-08-09	2020-02-13	The Board Of Regents Of The University Of Oklahoma	Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
TW202545984A (zh)	2017-08-09	2025-12-01	美商生物化學醫療公司	核酸分子及其用途
AU2019215063B2 (en)	2018-02-01	2025-10-16	Bioverativ Therapeutics, Inc.	Use of lentiviral vectors expressing Factor VIII
IL312315A (en)	2018-04-04	2024-06-01	Sigilon Therapeutics Inc	Implantable particles and related methods
BR112020022164A2 (pt)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	métodos de tratamento de hemofilia a
EP3823985A1 (de)	2018-07-16	2021-05-26	Baxalta Incorporated	Gentherapie von hämophilie a unter verwendung viraler vektoren, die für rekombinante fviii-varianten mit erhöhter expression codieren
WO2020033863A1 (en)	2018-08-09	2020-02-13	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es)	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh)	2019-01-16	2024-08-11	日商武田藥品工業股份有限公司	用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US20220233650A1 (en)	2019-06-19	2022-07-28	Bioverativ Therapeutics Inc.	Recombinant factor viii-fc for treating hemophilia and low bone mineral density
JP7803014B2 (ja)	2019-09-30	2026-01-21	バイオベラティブセラピューティクスインコーポレイテッド	レンチウイルスベクター製剤
EP4073106A2 (de)	2019-12-12	2022-10-19	Takeda Pharmaceutical Company Limited	Gentherapie von hämophilie a unter verwendung viraler vektoren, die für rekombinante fviii-varianten mit erhöhter expression codieren
WO2021165226A1 (en)	2020-02-17	2021-08-26	Biotest Ag	Subcutaneous administration of factor viii
US12173307B2 (en)	2020-06-24	2024-12-24	Bioverativ Therapeutics Inc.	Methods for the purification of viral vectors
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction
EP4355768A1 (de)	2021-06-14	2024-04-24	Takeda Pharmaceutical Company Limited	Gentherapie von hämophilie a unter verwendung von für rekombinante fviii-varianten codierenden viralen vektoren mit erhöhter expression
CA3229323A1 (en)	2021-08-23	2023-03-02	Ajay MAGHODIA	Optimized factor viii genes
CA3232988A1 (en)	2021-09-30	2023-04-06	Bioverativ Therapeutics Inc.	Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
EP4602155A1 (de)	2022-10-11	2025-08-20	Sigilon Therapeutics, Inc.	Manipulierte zellen und implantierbare elemente zur behandlung von krankheiten
TW202517669A (zh)	2023-07-05	2025-05-01	日商武田藥品工業股份有限公司	用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4027013A (en) *	1976-01-22	1977-05-31	William L. Wilson	Clottable fibrinogen free factor VIII and albumin product and process
US4348384A (en) *	1980-10-17	1982-09-07	Dainippon Pharmaceutical Co., Ltd.	Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4495175A (en) *	1982-08-05	1985-01-22	University Of Rochester	Preparation of highly purified human antihemophilic factor
US4746508A (en) *	1983-06-06	1988-05-24	Beth Israel Hospital Assn.	Drug administration
FI86885C (fi) *	1984-04-20	1992-10-26	Genentech Inc	Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
ATE72838T1 (de) *	1985-04-12	1992-03-15	Genetics Inst	Neue prokoagulierungsproteine.
US5451521A (en) *	1986-05-29	1995-09-19	Genetics Institute, Inc.	Procoagulant proteins
US5576194A (en) *	1986-07-11	1996-11-19	Bayer Corporation	Recombinant protein production
NO872932L (no) *	1986-07-18	1988-01-19	Gist Brocades Nv	Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
IL86693A (en) *	1987-06-12	1994-06-24	Stichting Centraal Lab	Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) *	1987-08-11	1990-06-15	Transgene Sa	Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4904584A (en) *	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
US5204323B1 (en) *	1988-10-06	1995-07-18	Ciba Geigy Corp	Hirudin antidotal compositions and methods
SE465222C5 (sv) *	1989-12-15	1998-02-10	Pharmacia & Upjohn Ab	Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5585112A (en) *	1989-12-22	1996-12-17	Imarx Pharmaceutical Corp.	Method of preparing gas and gaseous precursor-filled microspheres
SE468050C (sv) *	1991-03-15	1998-04-27	Pharmacia & Upjohn Ab	Rekombinant derivat av human faktor VIII
DE4111393A1 (de) †	1991-04-09	1992-10-15	Behringwerke Ag	Stabilisierte faktor viii-praeparationen
GB9122609D0 (en) †	1991-10-24	1991-12-04	Brownlee George G	Improvements relating to the treatment of haemophilia
GB9211538D0 (en) *	1992-06-01	1992-07-15	Blake David R	Antiinflammatory agent
DE69329795T2 (de) †	1992-10-02	2001-07-05	Genetics Institute, Inc.	Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) *	1992-11-13	1996-10-08	Genetics Institute, Inc.	Chimeric procoagulant proteins
WO1994011013A1 (en) *	1992-11-13	1994-05-26	Duke University	Chimeric blood coagulation proteins
SE9301581D0 (sv) *	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Protein formulation

1993
- 1993-07-05 SE SE9302308A patent/SE504074C2/sv not_active IP Right Cessation
1994
- 1994-03-23 ZA ZA942035A patent/ZA942035B/xx unknown
- 1994-03-30 MX MX9402339A patent/MX9402339A/es active IP Right Grant
- 1994-03-31 US US08/564,161 patent/US5972885A/en not_active Expired - Lifetime
- 1994-03-31 AT AT94915722T patent/ATE233099T1/de active
- 1994-03-31 SE SE9401105A patent/SE9401105D0/ unknown
- 1994-03-31 EP EP94915722A patent/EP0710114B2/de not_active Expired - Lifetime
- 1994-03-31 AU AU67627/94A patent/AU6762794A/en not_active Abandoned
- 1994-03-31 DE DE69432179T patent/DE69432179T3/de not_active Expired - Lifetime
- 1994-03-31 JP JP50398795A patent/JP3827713B2/ja not_active Expired - Fee Related
- 1994-03-31 DK DK94915722.6T patent/DK0710114T4/da active
- 1994-03-31 CA CA002163112A patent/CA2163112C/en not_active Expired - Fee Related
- 1994-03-31 PT PT94915722T patent/PT710114E/pt unknown
- 1994-03-31 ES ES94915722T patent/ES2193159T5/es not_active Expired - Lifetime
- 1994-03-31 WO PCT/SE1994/000297 patent/WO1995001804A1/en not_active Ceased

Also Published As

Publication number	Publication date
DE69432179T2 (de)	2003-07-24
CA2163112A1 (en)	1995-01-19
AU6762794A (en)	1995-02-06
EP0710114A1 (de)	1996-05-08
ES2193159T5 (es)	2011-07-29
JPH09500624A (ja)	1997-01-21
ES2193159T3 (es)	2003-11-01
DK0710114T4 (da)	2011-07-11
SE9302308L (sv)	1995-01-06
ZA942035B (en)	1995-01-05
PT710114E (pt)	2003-06-30
WO1995001804A1 (en)	1995-01-19
MX9402339A (es)	1995-01-31
ATE233099T1 (de)	2003-03-15
DK0710114T3 (da)	2003-06-23
DE69432179D1 (de)	2003-04-03
DE69432179T3 (de)	2012-01-19
SE9401105D0 (sv)	1994-03-31
JP3827713B2 (ja)	2006-09-27
CA2163112C (en)	2007-08-07
US5972885A (en)	1999-10-26
SE9302308D0 (sv)	1993-07-05
EP0710114B2 (de)	2011-03-16
EP0710114B1 (de)	2003-02-26

Legal Events

Date	Code	Title	Description
2013-09-03	NUG	Patent has lapsed

Publication	Publication Date	Title
SE504074C2 (sv)	1996-11-04	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0314095B1 (de)	1992-12-09	Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke
EP0315968B2 (de)	1997-04-09	Plasma- und Rekombinationsproteinformulierungen in einem Milieu niedriger Ionenstärke
EP0700299B1 (de)	2002-06-05	Sauerstoff reduzierte wässerige faktor viii-enthaltene lösung
US5605884A (en)	1997-02-25	Factor VIII formulations in high ionic strength media
JP3939750B2 (ja)	2007-07-04	凝固第ｖｉｉｉ因子の皮下、筋肉内または皮内投与用の製薬調合剤
EP0638091B1 (de)	2005-12-07	Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
EP0876155B1 (de)	2004-07-07	Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
JP3777467B2 (ja)	2006-05-24	安定化第ｖｉｉｉ因子調製物
JP3927248B2 (ja)	2007-06-06	Ｈｇｆ凍結乾燥製剤
AU2772092A (en)	1993-05-21	Treatment of haemophilia
US20020146409A1 (en)	2002-10-10	Methods for stabilizing lyophilized blood proteins
US20240342254A1 (en)	2024-10-17	Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained